![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PIPOX |
Gene summary for PIPOX |
![]() |
Gene information | Species | Human | Gene symbol | PIPOX | Gene ID | 51268 |
Gene name | pipecolic acid and sarcosine oxidase | |
Gene Alias | LPIPOX | |
Cytomap | 17q11.2 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q9P0Z9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51268 | PIPOX | NAFLD1 | Human | Liver | NAFLD | 9.45e-06 | 6.16e-01 | -0.04 |
51268 | PIPOX | HCC1_Meng | Human | Liver | HCC | 1.16e-53 | 1.41e-01 | 0.0246 |
51268 | PIPOX | HCC1 | Human | Liver | HCC | 7.94e-16 | 3.72e+00 | 0.5336 |
51268 | PIPOX | HCC2 | Human | Liver | HCC | 2.09e-19 | 3.31e+00 | 0.5341 |
51268 | PIPOX | HCC5 | Human | Liver | HCC | 1.83e-04 | 2.47e+00 | 0.4932 |
51268 | PIPOX | Pt14.b | Human | Liver | HCC | 7.01e-05 | 3.62e-01 | 0.018 |
51268 | PIPOX | S016 | Human | Liver | HCC | 1.94e-03 | 3.68e-01 | 0.2243 |
51268 | PIPOX | S027 | Human | Liver | HCC | 1.50e-06 | 9.77e-01 | 0.2446 |
51268 | PIPOX | S028 | Human | Liver | HCC | 8.31e-27 | 1.06e+00 | 0.2503 |
51268 | PIPOX | S029 | Human | Liver | HCC | 4.20e-23 | 1.10e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00463953 | Liver | NAFLD | carboxylic acid catabolic process | 73/1882 | 236/18723 | 4.16e-19 | 1.22e-15 | 73 |
GO:00160544 | Liver | NAFLD | organic acid catabolic process | 73/1882 | 240/18723 | 1.20e-18 | 2.34e-15 | 73 |
GO:00442825 | Liver | NAFLD | small molecule catabolic process | 91/1882 | 376/18723 | 8.96e-16 | 1.31e-12 | 91 |
GO:0009063 | Liver | NAFLD | cellular amino acid catabolic process | 36/1882 | 110/18723 | 6.56e-11 | 1.99e-08 | 36 |
GO:00065203 | Liver | NAFLD | cellular amino acid metabolic process | 63/1882 | 284/18723 | 1.14e-09 | 2.17e-07 | 63 |
GO:19016053 | Liver | NAFLD | alpha-amino acid metabolic process | 46/1882 | 195/18723 | 2.74e-08 | 2.86e-06 | 46 |
GO:00092596 | Liver | NAFLD | ribonucleotide metabolic process | 72/1882 | 385/18723 | 1.51e-07 | 1.09e-05 | 72 |
GO:00196936 | Liver | NAFLD | ribose phosphate metabolic process | 73/1882 | 396/18723 | 2.23e-07 | 1.53e-05 | 73 |
GO:00091177 | Liver | NAFLD | nucleotide metabolic process | 85/1882 | 489/18723 | 3.31e-07 | 2.18e-05 | 85 |
GO:00067537 | Liver | NAFLD | nucleoside phosphate metabolic process | 85/1882 | 497/18723 | 6.69e-07 | 3.83e-05 | 85 |
GO:00725217 | Liver | NAFLD | purine-containing compound metabolic process | 74/1882 | 416/18723 | 7.73e-07 | 4.27e-05 | 74 |
GO:1901606 | Liver | NAFLD | alpha-amino acid catabolic process | 25/1882 | 87/18723 | 8.67e-07 | 4.60e-05 | 25 |
GO:00091507 | Liver | NAFLD | purine ribonucleotide metabolic process | 67/1882 | 368/18723 | 1.10e-06 | 5.44e-05 | 67 |
GO:00061637 | Liver | NAFLD | purine nucleotide metabolic process | 70/1882 | 396/18723 | 1.93e-06 | 8.23e-05 | 70 |
GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
GO:0009066 | Liver | NAFLD | aspartate family amino acid metabolic process | 15/1882 | 49/18723 | 5.88e-05 | 1.30e-03 | 15 |
GO:00338653 | Liver | NAFLD | nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00338753 | Liver | NAFLD | ribonucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00340323 | Liver | NAFLD | purine nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00425582 | Liver | NAFLD | pteridine-containing compound metabolic process | 11/1882 | 33/18723 | 2.45e-04 | 4.09e-03 | 11 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa003108 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa04146 | Liver | NAFLD | Peroxisome | 19/1043 | 82/8465 | 4.37e-03 | 4.10e-02 | 3.30e-02 | 19 |
hsa0031011 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa041461 | Liver | NAFLD | Peroxisome | 19/1043 | 82/8465 | 4.37e-03 | 4.10e-02 | 3.30e-02 | 19 |
hsa0031041 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa041464 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
hsa002602 | Liver | HCC | Glycine, serine and threonine metabolism | 28/4020 | 40/8465 | 3.28e-03 | 1.07e-02 | 5.93e-03 | 28 |
hsa0031051 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa041465 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
hsa002603 | Liver | HCC | Glycine, serine and threonine metabolism | 28/4020 | 40/8465 | 3.28e-03 | 1.07e-02 | 5.93e-03 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIPOX | SNV | Missense_Mutation | c.134G>A | p.Arg45Gln | p.R45Q | Q9P0Z9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
PIPOX | SNV | Missense_Mutation | novel | c.994G>T | p.Asp332Tyr | p.D332Y | Q9P0Z9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-77-A5GB-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PIPOX | SNV | Missense_Mutation | novel | c.897N>A | p.Ser299Arg | p.S299R | Q9P0Z9 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-CR-6473-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | paclitaxel | SD |
PIPOX | SNV | Missense_Mutation | rs776309545 | c.383N>A | p.Arg128His | p.R128H | Q9P0Z9 | protein_coding | tolerated(0.45) | benign(0.017) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
PIPOX | SNV | Missense_Mutation | c.623A>G | p.Gln208Arg | p.Q208R | Q9P0Z9 | protein_coding | tolerated(0.43) | benign(0.003) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PIPOX | SNV | Missense_Mutation | rs142705261 | c.488G>A | p.Arg163Gln | p.R163Q | Q9P0Z9 | protein_coding | tolerated(0.58) | benign(0.013) | TCGA-BR-8368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PIPOX | SNV | Missense_Mutation | c.403N>T | p.Pro135Ser | p.P135S | Q9P0Z9 | protein_coding | tolerated(0.32) | benign(0.02) | TCGA-D7-6524-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
PIPOX | SNV | Missense_Mutation | rs201834259 | c.866N>A | p.Arg289His | p.R289H | Q9P0Z9 | protein_coding | tolerated(0.55) | benign(0) | TCGA-VQ-A8PO-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PIPOX | SNV | Missense_Mutation | novel | c.604N>A | p.Ala202Thr | p.A202T | Q9P0Z9 | protein_coding | tolerated(0.12) | benign(0.077) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
PIPOX | SNV | Missense_Mutation | novel | c.731N>A | p.Pro244Gln | p.P244Q | Q9P0Z9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DJ-A2QB-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |